Research Team Presents Promising Preliminary Results from TBI Study Using Myomo’s MyoPro
June 27 2018 - 8:00AM
Business Wire
Collaborative clinical trial, funded by U.S.
Department of Defense, examines the use of a myoelectric arm
orthosis to improve arm functionality in traumatic brain injury
patients
Researchers from the Northwestern University
Prosthetics-Orthotics Center (NUPOC) and the Cleveland VA Medical
Center have presented promising preliminary case reports from a
clinical trial that evaluates the effects of the MyoPro myoelectric
arm orthosis (powered brace) from Myomo on traumatic brain injury
(TBI) patients at the Cleveland VA Medical Center.
The study, which began in 2016 and is funded by the U.S.
Department of Defense, includes veterans and non-veterans with TBI
who have limited arm or hand functionality. Participants in the
study received nine weeks of therapy and training with the MyoPro,
followed by nine weeks of home use, with intermittent functional
evaluations.
The investigators presented interim findings at the American
Academy of Orthotists and Prosthetists Annual Scientific Meeting.
They reported that “people with long-standing TBI have improved
function when using a wearable myoelectric upper limb orthosis.
Among three study subjects, [they] reported a reduction of
spasticity and motor impairment as measured by the Modified
Ashworth Scale and Fugl-Meyer Assessment, respectively; and one
subject’s improvement in functional activity, as assessed by the
Chedoke Arm and Hand Activity Inventory,” according to a NUPOC
bulletin from March 2018.
Based on patented technology developed at MIT, MyoPro is the
only wearable myoelectric upper limb orthosis on the market. It is
a powered brace that senses a patient’s own EMG signals through
non-invasive sensors enabling a paralyzed or weakened arm to
function. This allows MyoPro users to perform activities of daily
living, including feeding themselves, carrying objects and doing
household tasks. Many patients are even able to return to work.
MyoPro is developed by Myomo (NYSE American: MYO), a wearable
medical robotics company.
Qualified veterans may receive MyoPro through U.S. Veterans
Administration Medical Centers across the country.
“MyoPro is restoring arm mobility and increased independence to
military and civilian TBI patients,” said Paul R. Gudonis, Chairman
and CEO of Myomo. “The preliminary results of this study are
encouraging. They show similar functional improvements in TBI
patients as with patients suffering arm and hand impairment from
stroke, spinal cord injury, brachial plexus injury and other
neuromuscular conditions that we have seen in previous studies and
in practice.”
For more information on the study visit
http://www.nupoc.northwestern.edu/docs/research/orthotics/marchisbraininjuryawarenessmonth_bulletin.pdf.
About MyomoMyomo, Inc. is a wearable medical robotics
company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb
orthosis designed to restore function to the weakened or paralyzed
arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular
disease or injury. It is currently the only marketed device that,
sensing a patient’s own EMG signals through non-invasive sensors on
the arm, can restore an individual’s ability to perform activities
of daily living, including feeding themselves, carrying objects and
doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. For more information, please visit
www.myomo.com.
Forward Looking StatementsThis press release contains
forward-looking statements regarding the Company's future business
expectations, including the potential benefits of our product in
increasing or restoring function in its users, and preliminary case
results from the NUPOC and Cleveland VA Medical Center study, which
are subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
only predictions and may differ materially from actual results due
to a variety of factors. Our actual results could differ materially
from those anticipated in these forward looking statements for many
reasons, including, without limitation, risks related to regulatory
approval and market acceptance of our products, and the other risk
factors contained in our filings made with the Securities and
Exchange Commission. More information about factors that
potentially could affect Myomo's financial results is included in
Myomo's filings with the Securities and Exchange Commission. The
Company cautions readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made.
The Company disclaims any obligation subsequently to revise any
forward-looking statements to reflect events or circumstances after
the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180627005349/en/
For Myomo:ir@myomo.comorInvestor Relations:PCG
AdvisoryVivian Cervantes,
646-863-6274vivian@pcgadvisory.comorPublic
Relations:GreenoughRachel Robbins,
617-275-6521rrobbins@greenough.biz
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024